FinnTrunk研究:大隐静脉主干激光消融联合与分期处理属支的早期随机对照结果
FinnTrunk为多中心、非盲、平行组随机对照试验,比较症状性静脉曲张患者接受单纯主干激光消融(ILA)与主干消融联合属支泡沫硬化剂(LA+FS)的早期结局。3个月时ILA组20.7%患者追加属支泡沫硬化治疗,LA+FS组为0.0%(p < .001);LA+FS手术时间更长但3个月静脉临床严重程度评分更低,并发症与生活质量相似。
要点
- 联合属支处理可减少3个月追加干预,但单纯主干消融对多数患者仍达标。
- LA+FS手术时间更长,3个月VCSS更低,并发症与生活质量无差异。
- 需延长随访评估联合处理优势的持久性。
核心结论
- 联合属支治疗虽显示部分早期临床优势,但单纯EVLA在多数患者中达到主要治疗目标,短期是可接受但略逊于联合方案的替代选择。
- 需延长随访以评估结果耐久性。
研究设计与样本
- 多中心、非盲、平行组随机对照试验(NCT04774939)。
- 纳入有症状性静脉曲张且大、小或前隐静脉反流需治疗的患者,随机分为ILA组与LA+FS组。
- ILA组接受单纯主干EVLA,LA+FS组接受主干EVLA联合超声引导泡沫硬化治疗属支。
- 主要结局为3个月时患者判定的追加属支干预需求。
- 把握度分析设定检测29.8%的追加干预率差异、允许14%脱落(α = 0.05,β = 0.20),所需样本量66例。
主要发现
- 3个月时ILA组20.7%患者追加属支UGFS,LA+FS组为0.0%(p < .001)。
- 手术时间中位数(IQR):ILA组46分钟(41,55),LA+FS组55分钟(49,63)(p < .001)。
- 3个月VCSS中位数(IQR):ILA组2.0(1.0,3.0),LA+FS组1.0(0.0,2.0)(p < .001)。
- 两组并发症率与3个月生活质量相似。
关键数值与推荐
- 主要结局阈值:3个月追加属支干预率ILA 20.7% vs LA+FS 0.0%(p < .001)。
- 手术时间中位数46分钟(IQR 41,55)vs 55分钟(IQR 49,63)(p < .001)。
- 3个月VCSS中位数2.0(IQR 1.0,3.0)vs 1.0(IQR 0.0,2.0)(p < .001)。
- 样本量计算:检测29.8%差异,允许14%脱落,α = 0.05,β = 0.20,需66例。
临床怎么用
- 对症状性静脉曲张行主干EVLA时,可考虑同期属支UGFS以减少短期追加干预并改善3个月症状评分。
- 单纯主干EVLA仍为多数患者可接受方案,但需告知短期追加属支干预的可能性较高。
- 联合方案手术时间更长,需结合患者意愿与资源安排选择。
局限性
- 非盲设计可能影响患者判定的主要结局。
- 随访仅3个月,无法评估长期耐久性。
- 样本量66例,规模较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Simultaneous treatment of tributaries alongside saphenous trunk ablation is considered the standard practice for managing symptomatic varicose disease. Nevertheless, uncertainty persists regarding the optimal timing of tributary treatment. This study aimed to compare early outcomes of concomitant vs. staged tributary treatment performed as an adjunct to saphenous trunk endovenous laser ablation (EVLA). METHODS: This was a multicentre, non-blinded, parallel arm, randomised controlled trial (NCT04774939). Patients with symptomatic varicose disease and great, small, or anterior saphenous vein reflux requiring treatment were randomised to isolated laser ablation (ILA) or laser ablation with foam sclerotherapy (LA+FS). Patients randomised to ILA received isolated EVLA of the saphenous trunk, and those randomised to LA+FS received saphenous trunk EVLA with concomitant ultrasound guided foam sclerotherapy (UGFS) of tributaries. The primary outcome was the need for additional tributary intervention at three months, as determined by the patient. A power analysis, set to detect a 29.8% difference in additional intervention rates, allowing a 14% dropout rate (α = 0.05, β = 0.20), indicated a required sample size of 66 patients. RESULTS: At three months, 20.7% of patients post ILA compared with 0.0% post LA+FS pursued additional UGFS of tributaries (p < .001). The median (interquartile range [IQR]) procedure time was shorter for ILA compared with LA+FS (median 46 minutes [IQR 41, 55] vs. 55 minutes [49, 63]; p < .001), with a higher three month Venous Clinical Severity Score following ILA (median 2.0 [IQR 1.0, 3.0] vs. 1.0 [IQR 0.0, 2.0]; p <.001). Complication rates and three month quality of life were similar between the groups. CONCLUSION: Despite some early clinical advantages seen with concomitant tributary treatment, isolated EVLA met the main therapeutic objectives in most patients, thereby representing an acceptable but slightly less effective alternative to concomitant tributary treatment in the short term. Extended follow up is needed to assess the durability of these results.
引用
- Rahman T, Viljamaa J, Firoozi K, et al. Early Outcomes of a Randomised Controlled Trial Comparing Concomitant with Staged Tributary Treatment as an Adjunct to Endovenous Laser Ablation of the Saphenous Trunk: The FinnTrunk Study. Eur J Vasc Endovasc Surg. 2026. PMID: 41580273. doi:10.1016/j.ejvs.2026.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。